Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.05.2022 | Case report

Lenvatinib/programmed cell death-1 receptor antagonists

Pain: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Mei J, et al. Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma. Frontiers in Oncology 11: 25 Feb 2021. Available from: URL: http://www.frontiersin.org/Oncology/about Mei J, et al. Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma. Frontiers in Oncology 11: 25 Feb 2021. Available from: URL: http://​www.​frontiersin.​org/​Oncology/​about
Metadaten
Titel
Lenvatinib/programmed cell death-1 receptor antagonists
Pain: case report
Publikationsdatum
01.05.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-15129-7

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Dexamethasone

Case report

Semaglutide

Case report

BCG

Case report

Clonazepam